No pharmacological treatments exist for active suicidal ideation (SI), but the glutamatergic modulator ketamine elicits rapid changes in SI. We developed data-driven subgroups of SI trajectories after ketamine administration, then evaluated clinical, demographic, and neurobiological factors that might predict SI response to ketamine.
Related Authors
Erica Martin Richards, MD, PhD
Chair and Medical Director, Department of Psychiatry and Behavioral Health, Sibley Memorial Hospital
Facebook
Twitter
YouTube
BROADCASTMED